2024 annual financial data
Spyre Therapeutics 2024 Operating income growth
Direct answer
Operating income growth was 13.92%.
Operating income was -208,566,000 USD and net income was -208,018,000 USD.
Operating cash flow was -157,410,000 USD.
Get free Spyre Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 886,000 USD
- Operating income
- -208,566,000 USD
- Net income
- -208,018,000 USD
- Operating cash flow
- -157,410,000 USD